Table 2.
Selected anticancer drugs that alter cytotoxicity when combined with DHA in MDA-MB-231 cells
| Enhanced cytotoxicitya | Attenuated cytotoxicityb | ||
|---|---|---|---|
| Drug code | Drug name | Drug code | Drug name |
| 92859 | Arsenic trioxide | 63878 | Cytarabine |
| 747971 | Sorafenib | 756645 | Crizotinib |
| 757441 | Axitinib | 743414 | Imatinib |
| 296961 | Amifostine | 3053 | Dactinomycin |
| 8806 | Melphalan | 180973 | Tamoxifemn |
| 698037 | Pemetrexed Disodium | 266046 | Oxaliplatin |
| 747974 | Raloxifene HCl | 721517 | Zoledronic acid |
| 754143 | Romidepsin | 719276 | Fulvestra |
ap < 0.01, bp < 0.05
MDA-MB231 cells were treated with individual drugs at concentrations of IC25 and IC50 and DHA at 25, 50, and 100 μM for 48 h. Cell viability was determined by MTS assay. Significant enhancement or attenuation of DHA’s cytotoxicity was determined by two-way ANOVA followed by paired analysis